Dexcom CEO Talks Stelo Launch, Broader Plans, And GLP1 Misconceptions

Medtech Insight spoke to Dexcom CEO Kevin Sayer, ahead of this year’s Advanced Technologies & Treatments for Diabetes conference, to get an update on the company’s recent news, future strategy and where he feels his company’s market is headed.

• Source: Shutterstock

Dexcom perfectly timed a series of announcements with the start of this year’s annual Advanced Technologies & Treatments for Diabetes conference, held in Florence, Italy.

On 5 March, the company announced that the US Food and Drug Administration cleared its Stelo blood glucose monitor (CGM),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diabetic Care

More from Device Area

Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation?

 

The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.

Tempus AI Buys Paige. AI For $81.25M To Help Build Largest Oncology Foundation Model

 
• By 

Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.

A Decade Of Breakthrough Devices: Cardiac And Orthopedic Products Dominate FDA Designations

 

The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.